Second opinion 10 min
Cancer Clinical Trials: How to Join and Whether It’s Worth It
How phases I–III differ, whether placebo is used, who can take part, what rights participants have and where to look for a suitable cancer clinical trial.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 16 October 2026
A clinical trial is a way to receive treatment that hasn’t yet become standard, under closer monitoring than usual. Whether it’s worth taking part depends on the phase of the trial, on what standard options you have, and on how ready you are for extra visits and uncertainty.
Below I explain how trials work, where the fears about placebo come from, who gets included and how to look for a suitable trial.
When to ask about a trial
Many patients only think about trials when the doctor says “the standard options have run out”. But that isn’t the only moment. It makes sense to ask about a trial:
- at a new diagnosis, especially if the tumour is rare or standard treatment gives modest results;
- at progression on the current line, when the next step is being chosen;
- when a rare molecular feature of the tumour is found for which there is no approved drug;
- when standard treatment is ruled out because of other health conditions.
The earlier you ask, the more choice you have: many trials only accept patients who haven’t yet had a particular treatment. Once you have started standard therapy, some options may close.
At the same time, a trial shouldn’t delay the treatment you need. Searching and screening take time, so ask your treating doctor how long you can wait — and keep the standard plan in mind in parallel.
What phases I, II and III are
Every new drug or approach goes through several phases. Each phase asks its own question, and that determines what you can expect.
| Phase | Main question | Number of participants (according to NCI) |
|---|---|---|
| I | Is the treatment safe, what are the side effects, what dose can people tolerate | Around 15–30 |
| II | Does the treatment work against a specific type of tumour | 50–100 |
| III | Is the new treatment better than the standard one in effectiveness and side effects | From 100 to several thousand |
| IV | Long-term safety and benefit of an already approved drug | Number not stated |
Phase I is the first use in people or a new combination. The focus here is safety and dose. There is a chance of benefit, but no one knows it in advance.
Phase II — the drug has already passed the safety check; now the question is whether the tumour shrinks.
Phase III compares the new treatment with the standard one. For a patient this is often the most straightforward option: you will receive either the current standard, the standard plus the new drug, or a new approach instead of the standard.
Randomisation: who decides which treatment I get
In phase III trials, participants are assigned to groups at random — this is called randomisation. Neither the doctor nor you decides; the allocation is random. This is needed so that the groups are comparable and the result doesn’t depend on whom the doctor considers “better suited” to the new treatment.
For you, this means that by agreeing to a randomised trial, you accept in advance that you may end up in the standard-treatment group. That isn’t “losing out” — the standard in such a trial is the best of what has been proven so far.
The placebo myth
The most common fear I hear is: “They’ll give me a dummy pill instead of treatment.” In oncology, this is almost never the case.
The US National Cancer Institute (NCI) states that placebos are rarely used in cancer treatment trials. The NCCN (US National Comprehensive Cancer Network) puts it even more firmly: placebos are almost never used alone in cancer clinical trials.
When a placebo is used, it is usually in a design of “standard treatment + placebo” versus “standard treatment + new drug”. In other words, no one is left without treatment. Placebo on its own is possible when there is simply no standard treatment for that situation — and you must be told this before you sign the consent form.
If the informed consent form doesn’t answer the question “what will I receive if I’m in the control group?”, don’t sign it until someone explains.
Inclusion and exclusion criteria: why you might not be accepted
Every trial has strict selection rules. They are needed so that the result is reliable and so that people for whom the risk is too high are not harmed. They usually take into account:
- the type and stage of the tumour;
- molecular features — for example, a specific mutation (more on these in my article “Targeted therapy and molecular tests”);
- which treatment you have already had and how many lines;
- your general condition, and how well your liver, kidneys and bone marrow are working;
- other health conditions and medicines;
- age.
Being turned down because of the criteria is not a judgement on your prognosis. It only means that this particular trial is asking a different question. Sometimes a neighbouring trial is a fit.
So don’t be surprised if you need extra blood tests, fresh scans or a repeat biopsy before you are enrolled: checking the criteria is a required part of screening, not a formality. Keep all your documents and discs — the research team will need them just as much as your treating doctor does.
Pros and cons of taking part
| Possible advantages | Possible drawbacks |
|---|---|
| Access to treatment that isn’t available outside the trial | The new treatment may turn out to be no better than the standard one |
| A chance that the new treatment will be more effective | Side effects may be unexpected or serious |
| More frequent check-ups and monitoring | Extra visits, tests, travel, paperwork |
| Contributing to the treatment of future patients | Constant testing can increase anxiety |
These points are listed by the UK charity Cancer Research UK, and I agree with them. I’d add one thing: in phase I trials, the benefit for an individual participant is the least predictable, and this needs to be weighed honestly.
Informed consent and the right to leave
In Russia, participants’ rights are set out in Article 43 of Federal Law No. 61-FZ “On the Circulation of Medicines”. Local rules in other countries differ in detail, so check the ones that apply where you are being treated. Under the Russian law:
- taking part is voluntary;
- before you start, you must be informed in writing about the drug and the nature of the trial, the expected effectiveness, safety and degree of risk, the aims and duration, what will be done if unexpected effects occur, the terms of compulsory insurance and confidentiality;
- your consent is confirmed by your signature on the patient information sheet;
- you have the right to withdraw from the trial at any stage.
Take the information sheet home, read it calmly, and discuss it with your family and your treating doctor. A good research team never rushes you to sign. You can leave at any time — and after you leave, you continue treatment outside the trial.
How to look for a trial
Start by asking your treating doctor: “Are there any suitable trials for me?” They know your diagnosis better than any database. In parallel, you can search on your own:
- ClinicalTrials.gov — the largest international registry. It has filters by country, diagnosis and recruitment status, and it often lists detailed inclusion criteria.
- National trial registries — many countries keep their own. In Russia, for example, it is the Ministry of Health registry of approved clinical trials at grls.rosminzdrav.ru, which can be searched by drug or protocol name and by date and lists the participating centres in Russia. Its protocol number can often be used to find the full criteria on ClinicalTrials.gov.
- Major cancer centres — many have pages listing their open trials.
Check the status and dates: if recruitment started long ago, it may already be closed. And don’t be put off by the technical language of the criteria — you can go through them with your doctor.
If you’d like to understand whether it makes sense to look for a trial in your situation, I’ll go through your documents in a second-opinion consultation. The question of a trial often comes up together with the question of a second opinion and the decision of the tumor board.
Questions to ask before taking part
- Which phase is this, and what exactly is being studied?
- What will I receive if I’m in the control group? Is there a placebo?
- Which side effects are already known, and who will treat them?
- How many visits, tests and hospital stays will be needed, and how far will I have to travel?
- Which costs does the trial cover, and which doesn’t it?
- What are my options if I decline or leave the trial?
- Who will manage my treatment, and whom do I contact at night if I get worse?
A clinical trial is neither an experiment on desperate people nor a “last chance” — it is one of the treatment options, with its own benefits and risks. The decision is made together with your treating doctor, and only once you understand what you are agreeing to.
Sources
- Phases of Clinical Trials — National Cancer Institute (NCI)
- Questions to Ask About Clinical Trials — National Cancer Institute (NCI)
- Clinical trials: printable handout — National Comprehensive Cancer Network (NCCN)
- Advantages and drawbacks of taking part in a clinical trial — Cancer Research UK
- Статья 43 Федерального закона № 61-ФЗ «Об обращении лекарственных средств». Права пациентов, участвующих в клиническом исследовании (Article 43 of Federal Law No. 61-FZ “On the Circulation of Medicines”: Rights of Patients Taking Part in a Clinical Trial) — ConsultantPlus, as amended on 4 August 2026
- Инструкция по поиску клинических исследований в реестре Минздрава (Guide to searching for clinical trials in the Russian Ministry of Health registry) — Kirov State Medical University, 2021
Watch me explain this on video
Short videos on my Instagram (in Russian)
Frequently asked questions
This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.
